ITRM vs. FBRX, ONCT, BIOR, QLI, LPCN, LUMO, UBX, ACST, APRE, and LSTA
Should you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include Forte Biosciences (FBRX), Oncternal Therapeutics (ONCT), Biora Therapeutics (BIOR), Qilian International Holding Group (QLI), Lipocine (LPCN), Lumos Pharma (LUMO), Unity Biotechnology (UBX), Acasti Pharma (ACST), Aprea Therapeutics (APRE), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical preparations" industry.
Iterum Therapeutics (NASDAQ:ITRM) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
Iterum Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 5.4% of Iterum Therapeutics shares are owned by insiders. Comparatively, 10.5% of Forte Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Iterum Therapeutics received 111 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 62.10% of users gave Iterum Therapeutics an outperform vote while only 56.82% of users gave Forte Biosciences an outperform vote.
Forte Biosciences is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Iterum Therapeutics presently has a consensus price target of $6.00, suggesting a potential upside of 279.63%. Forte Biosciences has a consensus price target of $2.75, suggesting a potential upside of 269.13%. Given Iterum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Iterum Therapeutics is more favorable than Forte Biosciences.
Forte Biosciences' return on equity of -94.27% beat Iterum Therapeutics' return on equity.
In the previous week, Iterum Therapeutics had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 3 mentions for Iterum Therapeutics and 2 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.43 beat Iterum Therapeutics' score of 0.63 indicating that Forte Biosciences is being referred to more favorably in the news media.
Summary
Iterum Therapeutics and Forte Biosciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Iterum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iterum Therapeutics Competitors List
Related Companies and Tools
